^
Association details:
| Biomarker: | STK11 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS- mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
Published date:
02/21/2022
Excerpt:
IMpower150 was an international, open-label, randomized, phase III trial of ACP or ABCP vs BCP in 1202 patients with NSCLC enrolled....In mSTK11 patients, longer OS was seen in the ABCP arm (median 12.1 months; HR 0.71; 95% CI 0.44 to 1.13) and similar OS in the ACP arm (median 7.7 months; HR 1.01; 95% CI 0.64 to 1.58) vs the BCP arm (median 9.9 months).
Secondary therapy:
Chemotherapy
DOI:
10.1136/jitc-2021-003027
Trial ID:
